Skip to main content

Table 2 Adverse Events*Related to Neoadjuvant gemcitabine and Concurrent IMRT (N = 47)

From: Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution

Adverse event

Grade 1–2, n (%)

Grade 3, n (%)

Grade 4–5, n (%)

White blood cell decreased

42(86%)

1(2%)

0(0%)

Neutrophil count decreased

28(57%)

1(2%)

0(0%)

Anemia

38(76%)

0(0%)

0(0%)

Platelet count decreased

30(61%)

1(2%)

0(0%)

Blood bilirubin increased

14(29%)

5(10%)

0(0%)

AST increased

22(45%)

5(10%)

0(0%)

ALT increased

25(51%)

6(12%)

0(0%)

Hypoalbuminemia

32(65%)

1(2%)

0(0%)

Serum AMY increased

10(20%)

4(8%)

0(0%)

Allergic reaction

3(6%)

1(2%)

0(0%)

Fatigue

20(41%)

0(0%)

-

Anorexia

24(49%)

0(0%)

0(0%)

Diarrhea

5(11%)

0(0%)

0(0%)

Mucositis/stomatitis

2(4%)

0(0%)

0(0%)

Nausea

22(45%)

0(0%)

-

Vomiting

8(16%)

0(0%)

0(0%)

Febrile neutropenia

-

0(0%)

0(0%)

Biliary tract infection

-

8(16%)

0(0%)

  1. *Events were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Abbreviations: IMRT intensity modulated radiotherapy, AST aspartate transaminase, ALT alanine transaminase, ALB albumin, AMY amylase